Page 162 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Pfannenstiel incision in endometrial cancer

doi: 10.3390/medicina60050733 2020;30(6):893-896.
28. Takenaka M, Kamii M, Iida Y, et al. Re-thinking the doi: 10.1136/ijgc-2020-001327
prognostic significance of positive peritoneal cytology in 36. Frumovitz M, Obermair A, Coleman RL, et al. Quality of life
endometrial cancer. Gynecol Oncol. 2021;161(1):135-142.
in patients with cervical cancer after open versus minimally
doi: 10.1016/j.ygyno.2021.01.007 invasive radical hysterectomy (LACC): A secondary
outcome of a multicentre, randomised, open-label, phase 3,
29. Padilla-Iserte P, Lago V, Tauste C, et al. Impact of uterine
manipulator on oncological outcome in endometrial cancer non-inferiority trial. Lancet Oncol. 2020;21(6):851-860.
surgery. Am J Obstet Gynecol. 2021;224:65-e1.e11. doi: 10.1016/S1470-2045(20)30081-4
doi: 10.1016/j.ajog.2020.07.025 37. Gultekin M, Dundar S, Kucukyildiz I, et al. Survival of
gynecological cancers in Turkey: Where are we at? J Gynecol
30. Machida H, Hom MS, Adams CL, et al. Intrauterine
manipulator use during minimally invasive hysterectomy Oncol. 2017;28(6):e85.
and risk of lymphovascular space invasion in endometrial doi: 10.3802/jgo.2017.28.e85
cancer. Int J Gynecol Cancer. 2018;28(2):208-219.
38. Kurosu H, Todo Y, Yamada R, et al. A BMI-category
doi: 10.1097/IGC.0000000000001181 distribution pattern of intrinsic and treatment-related
prognostic factors in endometrial cancer. Jpn J Clin Oncol.
31. Matsuo K, Klar M, Nusbaum DJ, et al. Utilization and
outcomes of sentinel lymph node biopsy for early 2021;51(5):722-727.
endometrial cancer. Obstet Gynecol. 2022;139(5):809-820. doi: 10.1093/jjco/hyaa274
doi: 10.1097/AOG.0000000000004733 39. Stuart GC, Kitchener H, Bacon M, et al. 2010 gynecologic
cancer intergroup (GCIG) consensus statement on clinical
32. Raffone A, Fanfani F, Raimondo D, et al. Predictive factors
of sentinel lymph node failed mapping in endometrial trials in ovarian cancer: Report from the fourth ovarian
carcinoma patients: A systematic review and meta-analysis. cancer consensus conference. Int J Gynecol Cancer.
Int J Gynecol Cancer. 2023;33(6):853-859. 2011;21:750-755.
doi: 10.1097/IGC.0b013e31821b2568
doi: 10.1136/ijgc-2022-004014
40. Alouini S, Bakri Y. Para-aortic lymphadenectomy in ovarian,
33. Baiocchi G, Andrade CEMC, Ribeiro R, et al. Sentinel
lymph node mapping versus sentinel lymph node mapping endometrial, gastric, and bladder cancers: A systematic
with systematic lymphadenectomy in endometrial cancer: review of randomized controlled trials. Cancers (Basel).
An open-label, non-inferiority, randomized trial (ALICE 2024;16(19):3394.
trial). Int J Gynecol Cancer. 2022;32(5):676-679. doi: 10.3390/cancers16193394
doi: 10.1136/ijgc-2022-003378 41. Ronsini C, Iavarone I, Vastarella MG, et al. SIR-EN-new
biomarker for identifying patients at risk of endometrial
34. Zammarrelli WA 3 ., Afonso AM, Broach V, et al. Sentinel
rd
lymph node biopsy in patients with endometrial cancer carcinoma in abnormal uterine bleeding at menopause.
and an indocyanine green or iodinated contrast reaction-a Cancers (Basel). 2024;16(21):3567.
proposed management algorithm. Gynecol Oncol. doi: 10.3390/cancers16213567
2021;162(2):262-267.
42. Lubiński J, Lener MR, Marciniak W, et al. Serum essential
doi: 10.1016/j.ygyno.2021.05.009 elements and survival after cancer diagnosis. Nutrients.
2023;15(11):2611.
35. Segarra B, Meyer LA, Malpica A, Bhosale P. Endometrial
cancer recurrence at multiple port sites. Int J Gynecol Cancer. doi: 10.3390/nu15112611

Volume 9 Issue 3 (2025) 154 doi: 10.36922/EJMO025150106